Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences

Pink Sheet's Drug Review Profile reveals FDA's second biosimilar got hung up on product quality concerns that suggested potential differences between Celltrion's CT-P13 and its reference biologic, Janssen's infliximab.

Celltrion Logo

The US regulatory review of Celltrion Inc.'s Inflectra, a biosimilar of Janssen Biotech Inc.'s Remicade, was waylaid by residual uncertainties about potential product quality differences that required additional analytical similarity data – and a second review cycle – before FDA was sufficiently confident that the product was highly similar to its reference biologic.

Inflectra (infliximab-dyyb, also known as CT-P13) was only the second biosimilar application to make it all the way through the FDA review and approval process, following Sandoz Inc.'s Zarxio (filgrastim-sndz)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Biosimilars & Generics